抢先看！今年ASCO乳腺癌领域都有哪些亮点？
2023年，第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日至6日举行，目前ASCO官网已公布了本次会议的日程和摘要题目。作为全球规模最大的肿瘤领域学术会议，世界一流的肿瘤学专家齐聚一堂，将国际最前沿的临床肿瘤学研究成果和治疗技术分享给参会者。对于肿瘤学者，ASCO年会是绝对不容错过的学术交流盛会。今天我们就先瞅一瞅乳腺癌领域有哪些新药新疗法“上新”值得追~
01
早期乳腺癌
高中数学参数方程摘要号：LBA500
橙子功效2023 ASCO
Ⅲ期NATALEE试验：瑞波西利+内分泌治疗辅助治疗HR+/HER2- 早期乳腺癌
Pha III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients
with HR+/HER2− early breast cancer
摘要号：501
2023 ASCO
阿贝西利联合内分泌治疗辅助治疗HR+/HER2- 淋巴结阳性高危早期乳腺癌: monarchE研究按年龄分层的疗效和安全性结局
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive，high-risk early breast cancer (EBC)
摘要号：502
2023 ASCO
肉炒土豆片
新辅助化疗和手术后进行循环肿瘤DNA检测以预测ER+/HER2-乳腺癌的早期复发：PENELOPE-B试验的分析感悟说
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relap in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
摘要号：LBA506
2023 ASCO
在HER2+ 早期乳腺癌患者中评价化疗降阶梯治疗的随机Ⅱ期 PHERGain 试验的3年无浸润性疾病生存期结局
再听妈妈的话3-year invasive dia-free survival (iDFS) of the strategy-bad, randomized pha II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)
摘要号：507
2023 ASCO
优美语句摘抄
增殖特征对sTIL-高和sTIL-低三阴性乳腺癌（TNBC）中的新辅助化学免疫疗法疗效的不同影响：NeoPACT试验的生物标志物分析
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial
摘要号：508
Nur's Day
是否可通过肿瘤浸润淋巴细胞预测曲妥珠单抗治疗HER2+ 乳腺癌的获益？——5项试验中4097例女性患者数据的荟萃分析
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials
摘要号：514| Poster Bd #: 344
珠字开头的成语2023 ASCO
I-SPY2研究中HER2低表达状态与分子亚型、治疗缓解和生存期的相关性
Correlation of HER2 low status in I-SPY2 with molecular subtype, respon, and survival
摘要号：LBA520| Poster Bd #: 350节
2023 ASCO
口服紫杉醇+卡铂+多塔利单抗（OPE/Cb/D）±曲妥珠单抗治疗早期高危乳腺癌：新辅助I-SPY 2试验的结果
Oral paclitaxel, Carboplatin, and Dostarlimab (OPE/Cb/D) without and with Trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
摘要号：522| Poster Bd #: 352
2023 ASCO
NeoRHEA的主要疗效分析：哌柏西利联合内分泌治疗新辅助治疗ER+/HER2- 乳腺癌的生物标志物研究
Primary efficacy analys of NeoRHEA, neoadjuvant biomarker rearch study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer
02
转移性乳腺癌
摘要号：LBA1000
2023 ASCO
HR+/HER2- 晚期乳腺癌患者选择CDK4/6抑制剂最佳治疗时机的3期 SONIA 试验 (BOOG 2017-03) 的主要结局分析
Primary outcome analysis of the pha 3 SONIA trial (BOOG 2017-03) on lecting the o
ptimal position of cyclin-dependent kinas 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
摘要号：1001
2023 ASCO
二线内分泌治疗联合或不联合哌柏西利维持治疗HR+/HER2- 晚期乳腺癌：PALMIRA试验
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
摘要号：1002
2023 ASCO
PADA-1试验随机分组后，芳香化酶抑制剂或氟维司群联合哌柏西利治疗后ESR1突变的类
型和动力学
Dynamics and type of ESR1 mutations under aromata inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial
摘要号：1003
2023 ASCO
戈沙妥珠单抗(SG)治疗HR+/HER2- 转移性乳腺癌的Ⅲ期 TROPiCS-02研究的最终总生存期分析
Final overall survival (OS) analysis from the pha 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
摘要号：1004
2023 ASCO
在转移性乳腺癌患者中进行的 HER3-DXd Ⅱ 期研究
A pha 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)
摘要号：1005
2023 ASCO
TNBC患者中的动态HER2低表达状态：重复活检的影响
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies
摘要号：1006
2023 ASCO产品手记
DESTINY-Breast01、-02和-03研究中T-DXd治疗HER2+ 转移性乳腺癌患者的年龄特异性汇总分析
An age-specific pooled analysis of trastuzumab deruxtecan (TDXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03
摘要号：1008
2023 ASCO
eHealth（CANKADO PRO-React版本）对接受哌柏西利和内分泌治疗的HR+/HER2- 转移性乳腺癌患者至生活质量恶化时间的影响：多中心随机 PreCycle 试验的主要结局分析
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial
